2020 American Transplant Congress
Comparative Review of Adult Kidney Transplant Medicare Cost Report Reimbursement in U. S. Transplant Hospitals
1Vanderbilt University Medical Center, Nashville, TN, 2Transplant Management Group, San Diego, CA
*Purpose: Medicare organ acquisition reimbursement (MOAR) from the Medicare Cost Report (MCR) includes but is not limited to costs associated with candidate evaluation, maintenance on…2020 American Transplant Congress
Characterizing the Impact of Medicaid Expansion on Pediatric Liver Transplantation
Johns Hopkins University, Baltimore, MD
*Purpose: Under the Patient Protection and Affordable Care Act (ACA), states have the option to expand Medicaid eligibility (ME) which has allowed for increased access…2020 American Transplant Congress
The Importance of Annual Medicare Part D Plan Evaluation
*Purpose: The Medicare open enrollment period is from Oct 15 to Dec 7, annually. The purpose of this project was to objectively measure the benefit…2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…2019 American Transplant Congress
Economic Impact of Donor Hepatitis C Kidney Transplantation: A Medicare Cost Analysis
*Purpose: In the era of highly effective direct-acting antiviral agents (DAAs), kidney transplant (KT) from Hepatitis C virus (HCV)-positive donors is increasingly considered as an…2019 American Transplant Congress
The Impact of Transplant Hospital Organ Procurement on Medicare Cost Report Reimbursement
*Purpose: Medicare organ acquisition reimbursement from the Medicare Cost Report includes costs associated with transplant hospitals acquiring an organ for Medicare transplant patients and the…2019 American Transplant Congress
Donor-derived Cell-free Dna In Donor Specific Antibody Positive Kidney Transplant Recipients
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker of kidney allograft injury. Studies examining the clinical validity of this biomarker have identified cut off…2019 American Transplant Congress
Insurance Status Impacts Treatment for Hepatocellular Carcinoma
*Purpose: Previous studies have identified treatment disparities in the treatment of hepatocellular carcinoma (HCC) based on insurance status and provider. Recent studies have shown more…2018 American Transplant Congress
Taking Your Center's Temperature: Using a Heat Map to Target Your Transplant-Specific Education for Regulatory Compliance
Medical University of South Carolina, Charleston.
Background: Large, multi-organ transplant centers struggle with implementation of a comprehensive strategy for development and execution of a Transplant-specific education plan. Regulatory requirements for staff…2018 American Transplant Congress
Cost Effectiveness of Lifelong Medicare Immunosuppressant Drug Coverage for Kidney Transplant Recipients in the Current Era
While there is no Medicare time limit for dialysis patients, kidney transplant recipients lose their Medicare coverage 36 months after they receive their transplant. The…
American Transplant Congress abstracts